Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia)

Background and Objectives: Pharmacogenomics (PGx) leverages genomic information to tailor drug therapies, enhancing precision medicine. Despite global advancements, its implementation in Lebanon, Qatar, and Saudi Arabia faces unique challenges in clinical integration. This study aimed to investigate PGx attitudes, knowledge implementation, associated challenges, forecast future educational needs, and compare findings across the three countries.
Methods: This cross-sectional study utilized an anonymous, self-administered online survey distributed to healthcare professionals, academics, and clinicians in Lebanon, Qatar, and Saudi Arabia. The survey comprised 18 questions to assess participants' familiarity with PGx, current implementation practices, perceived obstacles, potential integration strategies, and future educational needs.
Results: The survey yielded 337 responses from healthcare professionals across the three countries. Data revealed significant variations in PGx familiarity an..., Ethical statement and informed consent
Ethical approval for this study was obtained from the institutional review boards of the participating universities: Beirut Arab University (2023-H-0153-HS-R-0545), Qatar University (QU-IRB 1995-E/23), and Alfaisal University (IRB-20270). Informed consent was obtained from all participants online, ensuring their confidentiality and the right to withdraw from the study without any consequences. Participants were informed that all collected data would be anonymous and confidential, with only the principal investigator having access to the data. Completing and submitting the survey was considered an agreement to participate.
Study design
This study utilized a quantitative cross-sectional research design, involving healthcare professionals (pharmacists, nurses, medical laboratory technologists), university academics, and clinicians from Lebanon, Qatar, and Saudi Arabia. Data was collected through a voluntary, anonymous, private survey to gather PGx per..., , # **Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia)**

## Description of the data and file structure

* This is a data sheet exported as .CSV file from the original SPSS database.
* Methods of data processing and analysis: data were generated by SPSS software version 20 (SPSS, Inc., IL, USA). Details are included in the manuscript.
* No patient identifiers are included in these data sets.
* Specialized software used: these data need to be entered in SPSS.
* Description of the data set:
o 1 dataset is included; PGx_database : it includes the raw data of our paper.
o In the data set, each row represent one participant.
o All the variables can contain empty cells. When participants didn't answer, empty cells were added to show the missing data.
o The number in each cell has a specific value depending on the variable.

- Listed variables:

1. **ID**
* Description: Record identifier for each participant.
* Values: Nu...